Accéder au contenu
Merck

Metabolism of the predominant human milk oligosaccharide fucosyllactose by an infant gut commensal.

Scientific reports (2019-10-30)
Kieran James, Francesca Bottacini, Jose Ivan Serrano Contreras, Mariane Vigoureux, Muireann Egan, Mary O'connell Motherway, Elaine Holmes, Douwe van Sinderen
RÉSUMÉ

A number of bifidobacterial species are found at a particularly high prevalence and abundance in faecal samples of healthy breastfed infants, a phenomenon that is believed to be, at least partially, due to the ability of bifidobacteria to metabolize Human Milk Oligosaccharides (HMOs). In the current study, we isolated a novel strain of Bifidobacterium kashiwanohense, named APCKJ1, from the faeces of a four-week old breastfed infant, based on the ability of the strain to utilise the HMO component fucosyllactose. We then determined the full genome sequence of this strain, and employed the generated data to analyze fucosyllactose metabolism in B. kashiwanohense APCKJ1. Transcriptomic and growth analyses, combined with metabolite analysis, in vitro hydrolysis assays and heterologous expression, allowed us to elucidate the pathway for fucosyllactose metabolism in B. kashiwanohense APCKJ1. Homologs of the key genes for this metabolic pathway were identified in particular in infant-derived members of the Bifdobacterium genus, revealing the apparent niche-specific nature of this pathway, and allowing a broad perspective on bifidobacterial fucosyllactose and L-fucose metabolism.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Melibiose, ≥98% (HPLC)